ALNY icon

Alnylam Pharmaceuticals

418 hedge funds and large institutions have $16.5B invested in Alnylam Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 131 increasing their positions, 159 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

more call options, than puts

Call options by funds: $ | Put options by funds: $

less ownership

Funds ownership:

less funds holding

Funds holding:

less capital invested

Capital invested by funds: $ → $

18% less repeat investments, than reductions

Existing positions increased: 131 | Existing positions reduced: 159

21% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 68

25% less funds holding in top 10

Funds holding in top 10: 86 (-2)

Holders
418
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$486M
Puts
$346M
Net Calls
Net Calls Change

Top Buyers

1 +$626M
2 +$238M
3 +$90.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$48.6M
5
Morgan Stanley
Morgan Stanley
New York
+$40.8M

Top Sellers

1 -$251M
2 -$178M
3 -$131M
4
Invesco
Invesco
Georgia
-$117M
5
JPMorgan Chase & Co
JPMorgan Chase & Co
New York
-$92.7M
Name Holding Trade Value Shares
Change
Change in
Stake
1
$2.09B
2
$1.61B
3
$1.5B
4
$1.45B
5
$1.12B
6
$1.02B
7
$848M
8
$767M
9
$436M
10
$333M
11
$246M
12
$241M
13
$238M
14
$229M
15
$198M
16
$187M
17
$165M
18
$154M
19
$126M
20
$121M
21
$117M
22
$115M
23
$114M
24
$110M
25
$107M